ERBB2 and breast carcinoma: To further investigate subtype‐specific epidemiological factors and genetic susceptibility, we conducted subtype‐specific case–control studies based on patients with HER2‐zero and HER2‐low BC from above TBCCC and healthy controls from the Multi‐modality Independent Screening Trial (MIST) for breast cancer.